/

Empresas

Ne

No verificado

Neuraptive Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaHigiene alimentariaIndustriaSalud

2 Comunicados de prensa

Ver todos los comunicados de prensa

02/10/2025

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Defensa/Fuerzas Armadas

Industria

Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair

Fuente

Neuraptive Therapeutics, Inc.

Editor

1.00

0

11/09/2024

Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair

Fuente

Neuraptive Therapeutics, Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0